Last summer this pharmaceutical company was a single-digit stock but it has been on tear since. The stock did pull in sharply after topping out in the upper $80s in early March, but it has responded well and looks like it could be setting up for another leg higher.
Trading Plan:
Stop: below $68
Entry: break of wedge
Target: $78 then $86
Trading Plan:
Stop: below $68
Entry: break of wedge
Target: $78 then $86
